| pubmed-article:15493921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15493921 | lifeskim:mentions | umls-concept:C0003232 | lld:lifeskim |
| pubmed-article:15493921 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:15493921 | lifeskim:mentions | umls-concept:C0038317 | lld:lifeskim |
| pubmed-article:15493921 | lifeskim:mentions | umls-concept:C0439659 | lld:lifeskim |
| pubmed-article:15493921 | pubmed:issue | 42 | lld:pubmed |
| pubmed-article:15493921 | pubmed:dateCreated | 2004-10-20 | lld:pubmed |
| pubmed-article:15493921 | pubmed:abstractText | A key factor in the potential clinical utility of membrane-active antibiotics is their cell selectivity (i.e., prokaryote over eukaryote). Cationic steroid antibiotics were developed to mimic the lipid A binding character of polymyxin B and are shown to bind lipid A derivatives with affinity greater than that of polymyxin B. The outer membranes of Gram-negative bacteria are comprised primarily of lipid A, and a fluorophore-appended cationic steroid antibiotic displays very high selectivity for Gram-negative bacterial membranes over Gram-positive bacteria and eukaryotic cell membranes. This cell selectivity of cationic steroid antibiotics may be due, in part, to the affinity of these compounds for lipid A. | lld:pubmed |
| pubmed-article:15493921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15493921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15493921 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15493921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15493921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15493921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15493921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15493921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15493921 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15493921 | pubmed:issn | 0002-7863 | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:MotzA AAA | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:VoasRR | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:SavagePaul... | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:DingBangweiB | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:EvansonRichar... | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:SINDENJ AJA | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:Cardenas-Garc... | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:FanMingjinM | lld:pubmed |
| pubmed-article:15493921 | pubmed:author | pubmed-author:TurinGracijaG | lld:pubmed |
| pubmed-article:15493921 | pubmed:copyrightInfo | Copyright 2004 American Chemical Society | lld:pubmed |
| pubmed-article:15493921 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15493921 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:15493921 | pubmed:volume | 126 | lld:pubmed |
| pubmed-article:15493921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15493921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15493921 | pubmed:pagination | 13642-8 | lld:pubmed |
| pubmed-article:15493921 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:meshHeading | pubmed-meshheading:15493921... | lld:pubmed |
| pubmed-article:15493921 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15493921 | pubmed:articleTitle | Origins of cell selectivity of cationic steroid antibiotics. | lld:pubmed |
| pubmed-article:15493921 | pubmed:affiliation | Contribution from the Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84602, USA. | lld:pubmed |
| pubmed-article:15493921 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15493921 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15493921 | lld:pubmed |
